GHRP-6
C$36.99
For Research Use Only
GHRP-6 Peptide Overview
GHRP-6 is a synthetic hexapeptide, an analog of met-enkephalin, that induces growth hormone (GH) secretion by activating ghrelin receptors (GHS-R1a) without exhibiting typical opioid activity. It functions as a potent growth hormone secretagogue.
Mechanism of Action
GHRP-6 binds GHS-R1a in the hypothalamus and pituitary, triggering a G-protein–mediated cascade (via Gαq/11, PLC, IP₃, and DAG) that elevates intracellular calcium and activates PKC, ultimately stimulating GH release. Experimental data suggest that its full efficacy depends on endogenous GHRH, as co-administration with GHRH yields synergistic effects. Additionally, GHRP-6 may interact with CD36 receptors, contributing to cell survival pathways and modulating lipid metabolism, inflammation, and angiogenesis.
This peptide blend is provided for research and laboratory use only. Please review and adhere to our Terms and Conditions before ordering.
Quantity
Research Insights
-GHRP-6’s multifaceted role in GH modulation, energy homeostasis, and tissue protection continues to be a prominent focus in endocrine and metabolic research.
- Gastrointestinal Transit:In alloxan-induced diabetic mice, impaired gastric emptying and intestinal transit were significantly improved by GHRP-6 administration, while colonic transit remained unchanged.
- Neuroprotection:A one-week exposure to GHRP-6 in mouse models elevated IGF-1 mRNA levels in the hypothalamus, cerebellum, and hippocampus (not in the cortex). This was accompanied by increased phosphorylation of Akt and BAD, upregulation of the antiapoptotic protein Bcl-2, and enhanced IGFBP-5 expression in the hypothalamus, suggesting activation of IGF-1-mediated neuroprotective pathways.
- Muscle Anabolism:In cultured myoblasts, GHRP-6 enhanced expression of myogenic markers, IGF-1, and collagen type I, indicating anabolic effects. Comparative studies showed that GHRP-6 achieved GH peaks of approximately 15.7 ± 4.4 μg/L (AUC 674 ± 187 μg/L/90 min), exceeding those induced by GHRH (peak ~6.8 ± 1.1 μg/L, AUC 412 ± 71 μg/L/90 min).- Tissue Recovery:In murine models, chronic (30-day) GHRP-6 treatment accelerated wound healing and reduced hypertrophic scarring by attenuating inflammatory cytokines and fibrotic signals. In rat models of combined radiation and burn injury, GHRP-6 reduced TNF-α levels and, over 60 days, decreased liver fibrosis markers TGF-β and CTGF by 75% and over 60%, respectively.
-Hypothyroidism: In hypothyroid models, GHRP-6 (alone or with GHRH) elicits significantly higher GH secretion—possibly through somatostatin antagonism—compared to GHRH alone.
- Cortisol Release & Sleep: Administration of GHRP-6 enhances nocturnal GH and cortisol release, particularly increasing stage 2 sleep, without altering other EEG parameters.
- Organ Protection: GHRP-6 promotes a threefold increase in gut epithelial cell migration without affecting proliferation, and, in combination with EGF, reduces hepatic and intestinal damage and lipid peroxidation by 50–85% in experimental models.
Refrence
ibrián D, Ajamieh H, Berlanga J, León OS, Alba JS, Kim MJ, Marchbank T, Boyle JJ, Freyre F, Garcia Del Barco D, Lopez-Saura P, Guillen G, Ghosh S, Goodlad RA, Playford RJ. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond). 2006 May;110(5):563-73. https://pubmed.ncbi.nlm.nih.gov/16417467/
Zheng, Q., Qiu, W. C., Yan, J., Wang, W. G., Yu, S., Wang, Z. G., & Ai, K. X. (2008). Prokinetic effects of a ghrelin receptor agonist GHRP-6 in diabetic mice. World journal of gastroenterology, 14(30), 4795–4799. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739343/
Kristina Szabadfi, et al., Therapeutic Areas I: Central Nervous System, Pain, Metabolic Syndrome, Urology, Gastrointestinal and Cardiovascular, in Comprehensive Medicinal Chemistry II, 2007. https://www.sciencedirect.com/topics/medicine-and-dentistry/alloxan
Frago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology. 2002 Oct;143(10):4113-22. doi: 10.1210/en.2002-220261. PMID: 12239123.
Lim, C. J., Jeon, J. E., Jeong, S. K., Yoon, S. J., Kwon, S. D., Lim, J., Park, K., Kim, D. Y., Ahn, J. K., & Kim, B. W. (2015). Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I. BMB reports, 48(9), 501–506. https://doi.org/10.5483/bmbrep.2015.48.9.258
Cordido, F., Peñalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of clinical endocrinology and metabolism, 76(4), 819–823. https://doi.org/10.1210/jcem.76.4.8473389
Frieboes, R. M., Murck, H., Maier, P., Schier, T., Holsboer, F., & Steiger, A. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology, 61(5), 584–589. https://doi.org/10.1159/000126883
Mendoza Marí, Y., Fernández Mayola, M., Aguilera Barreto, A., García Ojalvo, A., Bermúdez Alvarez, Y., Mir Benítez, A. J., & Berlanga Acosta, J. (2016). Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plastic surgery international, 2016, 4361702. https://doi.org/10.1155/2016/4361702
Molecular Makeup
Molecular Formula: C₄₆H₅₆N₁₂O₆
- Molecular Weight: 873.03 g/mol
- Alternate Name: Growth Hormone Releasing Peptide-6